inclusion criteria: 1. the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, 2. subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, 3. chest image confirmed pulmonary involvement; 4. fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; 5. onset time ≤14 days; 6. agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; 7. the subjects had not taken aspirin for nearly one month prior to the screening period. 8. can follow the study or follow up procedure. -

inclusion criteria: 1. the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, 2. subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, 3. chest image confirmed pulmonary involvement; 4. fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; 5. onset time ≤14 days; 6. agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; 7. the subjects had not taken aspirin for nearly one month prior to the screening period. 8. can follow the study or follow up procedure. -

inclusion criteria: the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, chest image confirmed pulmonary involvement; fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; onset time ≤14 days; agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; the subjects had not taken aspirin for nearly one month prior to the screening period. can follow the study or follow up procedure. -

inclusion criteria: the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, chest image confirmed pulmonary involvement; fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; onset time ≤14 days; agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; the subjects had not taken aspirin for nearly one month prior to the screening period. can follow the study or follow up procedure. -

inclusion criteria: 1. the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, 2. subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, 3. chest image confirmed pulmonary involvement; 4. fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; 5. onset time ≤14 days; 6. agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; 7. the subjects had not taken aspirin for nearly one month prior to the screening period. 8. can follow the study or follow up procedure. -

inclusion criteria: 1. the patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent, 2. subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.the detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by real-time -pcr, 2. virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus, 3. chest image confirmed pulmonary involvement; 4. fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough; 5. onset time ≤14 days; 6. agree not to participate in another study until completion of the 14-day study; if you need to withdraw from this study; 7. the subjects had not taken aspirin for nearly one month prior to the screening period. 8. can follow the study or follow up procedure. -